Atara Biotherapeutics, an early-stage biotech targeting muscle loss in patients with end-stage renal disease, raised $55 million by offering 5 million shares at $11, below the range of $14 to $16. Atara Biotherapeutics plans to list on the NASDAQ under the symbol ATRA. Atara Biotherapeutics initially filed confidentially on 4/10/2014. Goldman Sachs and Citi acted as lead managers on the deal.
